164 related articles for article (PubMed ID: 18321472)
1. Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine.
Rahman Z; Ring RH; Young K; Platt B; Lin Q; Schechter LE; Rosenzweig-Lipson S; Beyer CE
Brain Res; 2008 Apr; 1203():68-78. PubMed ID: 18321472
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Beyer CE; Boikess S; Luo B; Dawson LA
J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP
Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386
[TBL] [Abstract][Full Text] [Related]
4. Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism.
Dawson LA; Nguyen HQ; Geiger A
Neuropharmacology; 1999 Aug; 38(8):1153-63. PubMed ID: 10462128
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice.
David DJ; Bourin M; Jego G; Przybylski C; Jolliet P; Gardier AM
Br J Pharmacol; 2003 Nov; 140(6):1128-36. PubMed ID: 14530210
[TBL] [Abstract][Full Text] [Related]
6. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.
Béïque J; de Montigny C; Blier P; Debonnel G
Neuropharmacology; 2000 Jul; 39(10):1800-12. PubMed ID: 10884561
[TBL] [Abstract][Full Text] [Related]
7. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat.
Béïque J; de Montigny C; Blier P; Debonnel G
Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562
[TBL] [Abstract][Full Text] [Related]
8. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
Béïque JC; de Montigny C; Blier P; Debonnel G
Synapse; 1999 Jun; 32(3):198-211. PubMed ID: 10340630
[TBL] [Abstract][Full Text] [Related]
9. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
Millan MJ; Gobert A; Lejeune F; Newman-Tancredi A; Rivet JM; Auclair A; Peglion JL
J Pharmacol Exp Ther; 2001 Aug; 298(2):565-80. PubMed ID: 11454918
[TBL] [Abstract][Full Text] [Related]
10. Evidence of the dual mechanisms of action of venlafaxine.
Harvey AT; Rudolph RL; Preskorn SH
Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.
Weikop P; Kehr J; Scheel-Krüger J
J Psychopharmacol; 2007 Nov; 21(8):795-804. PubMed ID: 17984160
[TBL] [Abstract][Full Text] [Related]
12. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
Millan MJ; Dekeyne A; Papp M; La Rochelle CD; MacSweeny C; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2001 Aug; 298(2):581-91. PubMed ID: 11454919
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
Felton TM; Kang TB; Hjorth S; Auerbach SB
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):297-305. PubMed ID: 12644903
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
15. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats.
Zhang R; Li X; Shi Y; Shao Y; Sun K; Wang A; Sun F; Liu W; Wang D; Jin J; Li Y
PLoS One; 2014; 9(3):e91775. PubMed ID: 24614602
[TBL] [Abstract][Full Text] [Related]
16. Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat.
Dawson LA; Li P
J Neural Transm (Vienna); 2003 Jun; 110(6):577-90. PubMed ID: 12768354
[TBL] [Abstract][Full Text] [Related]
17. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.
Deecher DC; Beyer CE; Johnston G; Bray J; Shah S; Abou-Gharbia M; Andree TH
J Pharmacol Exp Ther; 2006 Aug; 318(2):657-65. PubMed ID: 16675639
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex.
Hudson AL; Lalies MD; Silverstone P
Can J Physiol Pharmacol; 2012 Jun; 90(6):803-9. PubMed ID: 22512539
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor.
Engleman EA; Perry KW; Mayle DA; Wong DT
Neuropsychopharmacology; 1995 Jul; 12(4):287-95. PubMed ID: 7576005
[TBL] [Abstract][Full Text] [Related]
20. Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex.
Hatanaka K; Yatsugi S; Yamaguchi T
Eur J Pharmacol; 2000 Apr; 395(1):31-6. PubMed ID: 10781670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
